Vioxx Liability Exposure May Exceed 5-Year Product Sales Of $12 Bil.
Executive Summary
Merck's liability exposure from Vioxx could exceed total sales of the COX-2 inhibitor from its five years on the market
You may also be interested in...
Drug Population, Risk Should Receive Greater Attention In R&D – Wyeth VP
Pharmaceutical R&D should focus more on targeting appropriate populations and risk assessment rather than immediate blockbuster potential, Wyeth VP-Project & Portfolio Management Richard Heaslip suggested
Drug Population, Risk Should Receive Greater Attention In R&D – Wyeth VP
Pharmaceutical R&D should focus more on targeting appropriate populations and risk assessment rather than immediate blockbuster potential, Wyeth VP-Project & Portfolio Management Richard Heaslip suggested
Vioxx Withdrawal Fuels Criticism Of DTC; Liability Exposure May Be Test
The Vioxx withdrawal will prompt renewed debate over DTC advertising